***Included as part of the key loss of exclusivity (LOE) brands, FOURTH QUARTER PRODUCT AND PIPELINE UPDATE, In December, the company issued its 2021 Global Access Report that detailed Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. The company also plans to continue to explore the potential of Turning Point Therapeutics promising pipeline of novel compounds. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. 0000005488 00000 n
In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. Image Source: Zacks Investment Research. We do this in a few ways: We are a culture of savers who recognize the value of saving early and often and seize the opportunities to do so. The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. 0000002184 00000 n
Media: media@bms.com
0000005073 00000 n
Learn about joining our global team! Bristol Myers Squibb Bristol-Myers Squibb Company (BMY) will begin trading ex-dividend on September 30, 2021. In November, the company announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. Bristol-Myers Squibb 2021: Mark Your Calendar. With support and coaching from your colleagues, youre encouraged to take on stretch assignments that maximize your learning experience. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients., Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. hA 04Fq\GczC. A discussion of the non-GAAP financial measures is included under the Use of Non-GAAP Financial Information section. Working among other smart, creative and talented colleagues, youll find support and uncommon opportunities to learn, grow and lead. ET on February 18, 2022 by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 2150568. 0000014201 00000 n
**Included as part of the new product portfolio
None of our operations have been identified as having significant risk for incidents of child labor or forced labor. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Our Insights for Success program is offered to diverse employees to enhance their organizational and personal career success and ensure equitable leadership throughout the company. Available to US-based employeesChange location, Comparable to many others in the same league. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. <> The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer will answer questions about the company at 5 p.m. Bristol-Myers Squibb's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B. Your response will be removed from the review this cannot be undone. So we are always workingpushing the boundaries of what's possible to transform lives today and tomorrow. hb```b``{Ab,GU\r``8e/Gu
sMJM
;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com . No matter the role within BMS, we all embrace a patient-centric culture. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . Major Holidays. Christi Shaw just announced her resignation from the position of CEO of Kite. The tender offer described in this communication has not yet commenced. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. Bristol-Myers Squibb bulls will hope to hear the company announce they've not only beaten. They merged in 1989, creating a powerhouse pharmaceutical company that was the second-largest in the world at the time. Bristol Myers Squibb Paid Holidays 106 employees reported this benefit 4.3 20 Ratings Available to US-based employees Change location Employee Comments Showing 1-10 of 20 28 Jan 2023 4.0 Current Direcror in nullnull Comparable to many others in the same league Helpful Report 22 Dec 2022 4.0 By 1943, Squibb operated the largest penicillin production plant in the world in New Brunswick, New Jersey. Recently declared a week off fro everybody between xmas and new years. Show more Show less Resident Advisor Bucknell University . 0000006494 00000 n
Forward-looking statements are based on current expectations and projections about the companys future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the companys control and could cause the companys future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. The companys pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Wednesday, April 28th. 0000000016 00000 n
Home; Our Services; About us; Blog; Contact In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. Elizabeth Mily joined Bristol Myers Squibb Co. as executive vice president of strategy and business development in March 2020 after 27 years in investment banking. Ensured work schedule for each day was achieved and liaised with all key personnel as . We routinely post important information for investors on our website, BMS.com, in the Investors section. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. The benefit choices you make go into effect each January 1 (or on your date of eligibility, if later), and stay in effect through December 31, as long as you remain eligible for benefits. Cautionary Statement Regarding Forward-Looking Statements. 0000192879 00000 n
Supervised Warehouse staff. 0000193195 00000 n
Learn more! Employees must meet all eligibility requirements in order to qualify. There will be a conference call on February 4, 2022 at 8 a.m. 0000030151 00000 n
In a prespecified interim analysis, In January, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of, In December, the company announced two regulatory applications for, In December, the company announced new data and analyses from across its hematology portfolio (, In November, the company announced that the European Commission (EC) approved, In November, the company announced three regulatory applications for deucravacitinib have been accepted for review. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will Shares of Bristol Myers Squibb Co. BMY, -0.22% sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX, Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Our expansive library of resources covers a wide range of special interest topics in multiple languages through a variety of top learning and development resources powered by LinkedIn Learning. 0000008852 00000 n
Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. LICENSE AGREEMENT. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. (PDF). Bristol-Myers Squibb reported sales of $10.13 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.8%. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. ,,M|L7^`kBQv#
|88960\epmPZyC?r=
,L*P}``rN 0000010676 00000 n
Add to Microsoft Outlook. Drug Discovery and Translational Medicine, Equal Employment Opportunity / Disability Assistance. Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . All comparisons are made versus the same period in 2021 unless otherwise stated. BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. We believe in a Total Rewards experience that enriches your life today and engages and empowers you to save, perform, grow, and build toward all of your tomorrows. %%EOF Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. UA ** Included as part of the new product portfolio
0000030221 00000 n
Bristol Myers Squibb is also reaffirming its previously communicated 2020-2025 long-term targets: This financial guidance excludes the impact of any potential future strategic acquisitions and divestitures as well as any specified items as discussed under Use of Non-GAAP Financial Information. There is no reliable or reasonably estimable comparable GAAP measures for this non-GAAP financial guidance. We believe that success of our science is measured by the lives we touch. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. Use of Non-GAAP Financial Information and Financial Guidance, In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). . 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Materials on this website may contain information about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. They encouraged employees to take their vacations. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this communication that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. Bristol-Myers Squibb Co (BMY) Stock Price & News - Google Finance Home BMY NYSE Bristol-Myers Squibb Co Follow Share $69.30 After Hours: $69.30 (0.00%) 0.00 Closed: Mar 3, 4:02:47 PM GMT-5. 0000009073 00000 n
The recognition is a testament to our commitment to transform patients lives through science. 0000001987 00000 n
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. The FDA has accepted the NDA and the EMA has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. ET on February 4 through 11:30 a.m. 0000015083 00000 n
0000006923 00000 n
(link). Materials on this website may contain information about the Companys future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. (EPS) for full-year 2021 between $3.18 and $3.38, up from its previous forecast of a range of $3.12 to $3.32. Choosing Your Medical Plan. Investor Relations: investor.relations@bms.com Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow." Senior Research Investigator salaries ($93k), Research Investigator II salaries ($108k), Associate Research Scientist I salaries ($70k), Senior Research Investigator II salaries ($132k), Associate Research Scientist II salaries ($77k). The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Turning Point Therapeutics common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. )yJP Investors and the public can also access the live webcast by dialing in the U.S. toll free 877-502-9276 or international +1 313-209-4906, confirmation code: 2150568. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. We regularly promote awareness of this resource to employees. Shareholder proposals relating to our 2021 Annual Meeting of Shareholders must be received by us at our principal executive offices, Bristol-Myers Squibb Company, 430 East 29th Street14th Floor, New York, New York 10016, Attention: Corporate Secretary, no later than November 25, 2020. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibbs business nor reflect Bristol Myers Squibbs underlying business performance. 33 days holiday (inc. bank holidays) - prorated - with the option to buy/sell 5 additional days ; The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.1 billion, or $1.83 per share, in the fourth quarter, compared to non-GAAP net earnings of $3.3 billion, or $1.46 per share, for the same period a year ago. Agenus saw its stock skyrocket on Tuesday after the company announced a $1.6 billion deal with Bristol-Myers Squibb (NYSE: BMY), a $146 billion giant, to develop Agenus promising new cancer antibody treatment. endobj trailer Learn about joining our global team! Events and Presentations. 0000042788 00000 n
The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. TOKYO & NEW YORK, Jun 17, 2021--(BUSINESS WIRE)--Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). The company continues to maintain a consistent, balanced approach to capital allocation focused on prioritizing investment for growth through business development along with reducing debt, commitment to dividend growth and share repurchase. These documents will be available at no charge on the SECs website at www.sec.gov. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. Apr 2021 - Oct 2022 1 year 7 months. Turning Point Therapeutics Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer. Investor Relations: investor.relations@bms.com, Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021, https://www.businesswire.com/news/home/20220204005037/en/, Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by. I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively, said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. Available to US-based employeesChange location, Comparable to many others in the same league.